** Shares of drug developer Fractyl Health GUTS.O rise 6.7% to $1.27 premarket
** Co says early-stage data shows its weight management device Revita helps maintain weight in patients after they discontinued taking weight-loss drugs
** One month post-procedure, seven patients experienced an average weight regain of just 1.2%, compared with the ~3% typically observed at this time period after GLP-1 discontinuation based on prior clinical studies - GUTS
** Co expects to announce additional data from the study during Q3 of this year
** Shares of the company have fallen 42.2% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com ))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。